| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD
- Poster presentation to showcase method used to develop a first-of-its-kind assay to measure target engagement of an AβO-selective antibody
- On track to initiate a Phase 2 trial evaluating sabirnetug in the first half of 2024
- Sabirnetug is the nonproprietary name for ACU193 now accepted by the United States Adopted Name (USAN) Council and the International Nonproprietary Names (INN) Programme
CHARLOTTESVILLE, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will be presenting biomarker data and target engagement methods in an oral and poster presentation, respectively, at the upcoming International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), taking place March 5-9, 2024, in Lisbon, Portugal, and online.
Acumen's sabirnetug (ACU193) is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration. Positive topline results from 62 participants in the Phase 1 INTERCEPT-AD trial (NCT04931459) showed sabirnetug to be well-tolerated with a favorable overall safety profile. Study findings including statistically significant, dose-related amyloid plaque reduction comparable to approved and in-review amyloid-directed therapies at similar time points, low overall levels of ARIA-E, and pharmacokinetic data that confirmed proof-of-mechanism, support sabirnetug's potential to offer differentiated safety and efficacy as a next-generation treatment for early AD.
"We're proud to have generated one of the most robust Phase 1 datasets in the AD space to-date from INTERCEPT-AD and look forward to presenting key findings from some of our extensive exploratory analyses at this year's AD/PD meeting," said Daniel O'Connell, Chief Executive Officer of Acumen. "Fluid biomarkers are of particular interest in the AD field and will continue to advance our understanding of the therapeutic potential of differentiated mechanisms that target soluble, non-plaque forms of Aβ. Our initial findings from the Phase 1 study are promising and sabirnetug's effect on biomarkers will be further explored in our Phase 2 trial to be initiated in the first half of this year."
Posted In: ABOS
